SG Americas Securities
ARQT icon

SG Americas Securities’s Arcutis Biotherapeutics ARQT Stock Holding History

SG Americas Securities’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
58,259
+18,433
+46% +$429K ﹤0.01% 1637
2026
Q1 		$938K Buy
39,826
+4,597
+13% +$117K ﹤0.01% 1793
2025
Q4 		$1.02M Buy
35,229
+17,814
+102% +$456K ﹤0.01% 1998
2025
Q3 		$328K Buy
+17,415
New +$275K ﹤0.01% 2416
2025
Q2 		– Sell
-32,566
Closed -$509K – 2925
2025
Q1 		$509K Sell
32,566
-15,521
-32% -$219K ﹤0.01% 1758
2024
Q4 		$670K Buy
48,087
+9,754
+25% +$107K ﹤0.01% 1104
2024
Q3 		$356K Sell
38,333
-60,828
-61% -$600K ﹤0.01% 1988
2024
Q2 		$922K Buy
99,161
+83,452
+531% +$755K 0.01% 1342
2024
Q1 		$156K Sell
15,709
-8,647
-36% -$64.5K ﹤0.01% 2166
2023
Q4 		$79K Buy
+24,356
New +$66.2K ﹤0.01% 2830
2023
Q3 		– Sell
-28,414
Closed -$271K – 3097
2023
Q2 		$271K Buy
28,414
+2,932
+12% +$32.5K ﹤0.01% 1663
2023
Q1 		$280K Buy
+25,482
New +$369K ﹤0.01% 2171
2022
Q4 		– Sell
-11,296
Closed -$216K – 3053
2022
Q3 		$216K Sell
11,296
-2,350
-17% -$53.2K ﹤0.01% 2258
2022
Q2 		$291K Buy
+13,646
New +$280K ﹤0.01% 2396
2022
Q1 		– Sell
-8,251
Closed -$171K – 2950
2021
Q4 		$171K Sell
8,251
-11,532
-58% -$230K ﹤0.01% 2746
2021
Q3 		$473K Sell
19,783
-5,065
-20% -$116K ﹤0.01% 2564
2021
Q2 		$678K Buy
24,848
+2,066
+9% +$58.2K ﹤0.01% 1790
2021
Q1 		$659K Buy
+22,782
New +$711K ﹤0.01% 1817
2020
Q3 		– Sell
-8,142
Closed -$246K – 2698
2020
Q2 		$246K Buy
8,142
+4,456
+121% +$129K ﹤0.01% 2686
2020
Q1 		$110K Buy
+3,686
New +$99K ﹤0.01% 2925

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SG Americas Securities's ARQT Position: Q2 2026 in Review

SG Americas Securities increased its Arcutis Biotherapeutics (ARQT) stake by 46% in Q2 2026, buying an estimated $429K and bringing the position to 58,259 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

SG Americas Securities first reported a position in ARQT in Q1 2020 and has held it in 20 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • SG Americas Securities held 58,259 shares of Arcutis Biotherapeutics worth $1.53M as of Q2 2026.
  • SG Americas Securities bought 18,433 Arcutis Biotherapeutics shares in Q2 2026, an estimated $429K.
  • Arcutis Biotherapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1637 holding.
  • SG Americas Securities first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 20 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.